Contribute Try STAT+ Today

Good morning, everyone, and nice to see you after an extended holiday break. We hope the new year somehow got off to a good start, despite the drumbeat of challenging news out there. What can you do, though, but persevere? After all, the world manages to keep spinning. On that note, please join us for a much-needed cup of stimulation — our choice today is caramel vanilla cream — as we forage for items of interest. Speaking of which, here are some tidbits to help you get started. Hope the day goes well, and do keep in touch. …

The U.S. government is considering giving some people half the dose of the Moderna (MRNA) Covid-19 vaccine in order to speed vaccinations, Reuters says. Officials are in talks with Moderna and the Food and Drug Administration about stretching supplies of the vaccine, which requires two shots. “We know that for the Moderna vaccine, giving half of the dose to people between the ages of 18 and 55, two doses, half the dose … means exactly achieving the objective of immunizing double the number of people with the doses we have,” said Moncef Slaoui, who heads Operation Warp Speed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.